5-(dimethylamino)-2-formylphenyl acetate | 174269-30-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚酯
• 英文名称: 5-(dimethylamino)-2-formylphenyl acetate
• 英文别名: [5-(Dimethylamino)-2-formylphenyl] acetate
• CAS: 174269-30-8
• 化学式: C₁₁H₁₃NO₃
• 分子量: 207.229
• InChiKey: LWJPZHBPQCIYLV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-(dimethylamino)-2-formylphenyl acetate 在 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 18-冠醚-6 、 溴 、 O,O'-双(2,2,2-三氟乙基)磷乙酸甲酯 、 双(三甲基硅烷基)氨基钾 、 溶剂黄146 、 cesium fluoride 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 8.0h， 生成 7-(Dimethylamino)-6-(4-fluorophenyl)chromen-2-one
  参考文献：
  名称：

  6-Arylcoumarins as Novel Nonsteroidal Type Progesterone Antagonists: An Example with Receptor-Binding-Dependent Fluorescence

  摘要：

  Various 6-arylcoumarin derivatives were designed and synthesized as candidate nonsteroidal type progesterone antagonists. 6-Bromocoumarin derivatives were prepared from the corresponding 4-substituted 2-acetoxy-5-bromobenzaldehyde by employing the Still-Gennari modification of the Horner-Wadsworth-Emmons olefination reaction and were converted to 6-arylcoumarins by means of Suzuki-Miyaura cross-coupling reactions. The biological activities of these coumarin derivatives were evaluated by means of alkaline phosphatase assay in the T47D human breast carcinoma cell line. Among the synthesized compounds, 36 (IC(50) = 0.12 mu M) and 38 (IC(50) = 0.06 mu M), bearing a five-membered heterocycle, showed potent PR antagonist activity. Competitive binding assay showed that compounds 8 and 34 have potent PR binding affinity. The fluorescence of compound 8 was dependent on the solvent properties and was increased in the presence of PR ligand binding domain. This property might be applicable to the development of fluorescence probes for studies on PR.

  DOI：

  10.1021/jm2005404
• 作为产物：
  描述：

  3-羟基-N,N-二甲基苯胺 在 三乙胺 、 三氯氧磷 作用下， 以 二氯甲烷 为溶剂， 反应 5.0h， 生成 5-(dimethylamino)-2-formylphenyl acetate
  参考文献：
  名称：

  [EN] ACYL SULFONAMIDES FOR TREATING CANCER
  [FR] ACYLSULFONAMIDES POUR LE TRAITEMENT DU CANCER

  摘要：

  本发明提供了一般式(I)的酰基磺酰胺化合物：其中X、R1、R2、R3、R4、R5、R6、Ra和Rb如本文所述和定义的那样，制备所述化合物的方法，用于制备所述化合物的有用中间体化合物，包含所述化合物的药物组合物和组合物，以及利用所述化合物制造用于治疗或预防疾病的药物组合物，特别是治疗或预防过度增殖性疾病的药物组合物，作为唯一药剂或与其他活性成分结合使用，以及治疗和/或预防疾病的方法，特别是癌症，更特别是KAT6A和/或KAT6B在局部扩增的癌症，所述方法包括向需要的受试者施用至少一种式(I)化合物的有效量。

  公开号：

  WO2020216701A1

文献信息

• ACYL SULFONAMIDES FOR TREATING CANCER
  申请人：Bayer Aktiengesellschaft

  公开号：US20220226279A1

  公开（公告）日：2022-07-21

  The present invention provides acyl sulfonamide compounds of general formula (I): in which X, R 1 , R 2 , R 3 , R 4 , R 5 , R 6′ R a and R b are as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients as well as methods of treating and/or prophylaxing diseases, particularly cancer, more particularly cancer in which KAT6A and/or KAT6B is focally amplified, said method comprising administering an effective amount of at least one compound of formula (I) to a subject in need thereof.